Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,364 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Syringe Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Reality for the Management of Pain and Anxiety for Outpatient Interventional Radiology Procedures

NCT06150963
View directory record Official record
Conditions
Pain, Anxiety
Interventions
Virtual Reality, Standard Procedure Thyroid Biopsy, Standard Procedure PICC Placement
Device · Procedure
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 30, 2026, 6:10 AM EDT
Terminated Not applicable Interventional Results available

The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures

NCT02051933
View directory record Official record
Conditions
Equinus Contracture
Interventions
Botulinum toxin type A, sodium chloride
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

NCT04491006
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
ATH-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
55 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Santa Ana, California • West Palm Beach, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

NCT01500278
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
Biological · Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 30, 2026, 6:10 AM EDT
Recruiting Phase 3 Interventional

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

NCT06708299
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
CardiolRx
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

NCT01350947
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia
Interventions
5-Azacitidine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Buffalo, New York • Portland, Oregon • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 30, 2026, 6:10 AM EDT
Enrolling by invitation Phase 4 Interventional

Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery

NCT06995352
View directory record Official record
Conditions
Moderate-to-severely Painful Ankle Surgery
Interventions
Popliteal nerve block including liposomal bupivacaine, Adductor canal nerve block including liposomal bupivacaine, Continuous popliteal nerve block with normal saline, Popliteal nerve block with exclusively unencapsulated bupivacaine, Adductor canal nerve block with exclusively unencapsulated bupivacaine, Continuous popliteal nerve block with unencapsulated bupivacaine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Propranolol for Protracted Labor

NCT04741698
View directory record Official record
Conditions
Labour;Obstructed, Labor Dystocia
Interventions
Propranolol
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 30, 2026, 6:10 AM EDT
Active, not recruiting Phase 2 Interventional

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

NCT06824987
View directory record Official record
Conditions
APOL1-Mediated Kidney Disease
Interventions
AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
Combination Product · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
86
States / cities
Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

NCT07770685
View directory record Official record
Conditions
Glaucoma
Interventions
ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS

NCT05323708
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bmab 1000, Prolia®
Biological
Lead sponsor
Biocon Biologics UK Ltd
Industry
Eligibility
28 Years to 55 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 30, 2026, 6:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pancreas Ultrasound Imaging in type1 Diabetes

NCT05482321
View directory record Official record
Conditions
Type1diabetes, Insulitis, Pancreas Inflamed
Interventions
Definity Suspension for Injection
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

NCT01074008
View directory record Official record
Conditions
Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions
ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 30, 2026, 6:10 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

NCT04157335
View directory record Official record
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions
Benralizumab 30 mg, Matched placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Not applicable Interventional

The Impact of Holding on Stress and Bonding in Mother-Infant Pairs During Therapeutic Hypothermia

NCT03837717
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Neonatal Encephalopathy
Interventions
Holding, Saliva collection, No Holding
Behavioral · Other
Lead sponsor
MaineHealth
Other
Eligibility
24 Hours to 2 Days
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 30, 2026, 6:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Prevention of Postpartum Smoking Relapse and Related Health Consequences by Breastfeeding Promotion

NCT07661550
View directory record Official record
Conditions
Smoking ( Cigarette), Breastfeeding
Interventions
Breastfeeding promotion, Attention placebo control
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

NCT04333147
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Otilimab (GSK3196165), csDMARD(s)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
79
States / cities
Anniston, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

NCT01471574
View directory record Official record
Conditions
Hepatitis C, Genotype 1
Interventions
Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 4 Interventional

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

NCT01893996
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
Jonathan Graf
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT00851890
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 30, 2026, 6:10 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

NCT01406197
View directory record Official record
Conditions
Preterm Labor
Interventions
Experimental: Vaginal progesterone, Experimental: Topical progesterone, Experimental: Intramuscular progesterone
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
17 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 4 Interventional

Morphine PK Subgroup Analysis

NCT01322191
View directory record Official record
Conditions
Post Operative Pain
Interventions
Morphine
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 30, 2026, 6:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

NCT03268603
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis
Interventions
Autologous Adipose-derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 30, 2026, 6:10 AM EDT